Linezolid chemical structure
Find information on thousands of medical conditions and prescription drugs.

Zyvox

Linezolid is a synthetic systemic antibiotic drug. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Zafirlukast
Zagam
Zalcitabine
Zaleplon
Zanaflex
Zanamivir
Zantac
Zarontin
Zelnorm
Zerit
Zestoretic
Zestril
Zetia
Zevalin
Ziagen
Zidovudine
Zileuton
Ziprasidone
Zithromax
Zocor
Zofran
Zoladex
Zoledronic acid
Zolmitriptan
Zoloft
Zolpidem
Zometa
Zomig
Zonegran
Zonisamide
Zopiclone
Zosyn
Zovia
Zovirax
Zyban
Zymar
Zyprexa
Zyrtec
Zyvox

It was the first commercially available oxazolidinone antibiotic and is usually reserved for the treatment of serious bacterial infections where older antibiotics have failed due to antibiotic resistance. Conditions such as skin infections or nosocomial pneumonia where methicillin or penicillin resistance is found are indicators for linezolid use. Compared to the older antibiotics it is quite expensive.

The drug works by inhibiting the initiation of bacterial protein synthesis; it is the only antibiotic to work in this manner. That and its synthetic nature raised hopes that bacteria would be unable to develop resistance to it and also remove the chance of cross-resistance. (However, in 1997 Staphylococcus aureus was first identified in Japan as being resistant to linezolid.) Linezolid is effective against gram-positive pathogens, notably Enterococcus faecium, Staphylococcus aureus, Streptococcus agalactiae, Streptococcus pneumoniae, and Streptococcus pyogenes. It has almost no effect on gram-negative bacteria and is only bacteriostatic against most Enterococcus species.

The oxazolidinone class was discovered by researchers at E.I. duPont de Nemours and reported in 1987. Pharmacia Corporation developed linezolid and FDA approval was granted in April 2000. It is sold in the US under the tradename Zyvox in either tablet form, oral suspension powder, or in an inactive medium for intravenous injection.

Adverse effects

Side effects include rashes, loss of appetite, diarrhea, nausea, constipation and fever. A small number of patients will incur a severe allergic reaction, or tinnitis, or pseudomembranous colitis, or thrombocytopenia. Linezolid is a weak monoamine oxidase inhibitor (MAOI) and cannot be used with tyramine containing foods or pseudoephedrine.

Linezolid is toxic to mitochondria (probably because of the similarity of mitochondrial ribosomes to bacteria mitochondria). Signs of mitochondrial toxicity include lactic acidosis and peripheral neuropathy (Soriano et al., 2005).

Read more at Wikipedia.org


[List your site here Free!]


Will linezolid eradicate MRSA from surgical sites?
From American Family Physician, 10/1/05 by Anne D. Walling

Site infections are a major cause of surgical morbidity. The proportion of infections caused by methicillin-resistant Staphylococcus aureus (MRSA) has been increasing rapidly and is now believed to be at least 30 percent. MRSA infections have substantially higher morbidity, mortality, and health care costs than infections caused by other pathogens. Because most antibiotics are ineffective against MRSA, vancomycin (Vancocin) has become the most commonly used treatment even though it has limited effectiveness and requires intravenous administration. A new class of drugs, oxazolidinones, is available in oral formulations that may have effectiveness comparable with vancomycin. Weigelt and colleagues compared linezolid (Zyvox) with vancomycin in a randomized, open-label clinical trial of patients with complicated surgical site infections.

Patients were selected for the study if they had local erythema of skin and soft tissues requiring hospital admission, plus at least one feature of systemic infection such as fever, hypothermia, hypotension, elevated white blood cell count, or more than 15 percent immature neutrophils. Patients younger than 18 years and those with gram-negative infections were excluded from the study. Patients with serious medical comorbidities or infected devices, those already receiving an investigational medication, and those with contraindications to the study medications also were excluded. On entry to the study, demographic data were gathered with extensive documentation of the infection and clinical condition. Patients were not permitted any antibiotic medication with anti-MRSA activity for 48 hours before randomization. The patients were randomized to receive linezolid 600 mg twice daily or vancomycin 1 g every 12 hours. Patients were treated from four to 21 days.

The researchers considered outcomes from several perspectives. Patients in the intent-to-treat group received at least one dose of the study medication. The modified intent-to-treat group included patients who had culture-confirmed gram-positive pathogens at baseline. The clinically evaluable group included all patients who received at least four days of therapy and returned for test-of-cure evaluation. The primary outcome was clinical response and microbiologic cure. Clinical response documented the resolution of signs and symptoms on a three-point scale. Microbiologic cure used a four-point scale to document eradication of the pathogen, microbiologic persistence, indeterminate results, or missing data.

Although linezolid had better clinical outcomes than vancomycin in all groups, the difference did not reach statistical significance. Conversely, the microbiologic eradication rate was 84 percent in the 49 evaluable patients who received linezolid compared with 58 percent eradication in the 49 comparable patients treated with vancomycin (P = .0073). Similar results were obtained when only patients with documented MRSA were considered (i.e., microbiologic cure in 87 percent for linezolid compared with 48 percent for vancomycin). Linezolid also had a better microbiologic cure rate in patients with methicillin-sensitive organisms, but this difference did not reach statistical significance (89 percent compared with 56 percent). Adverse events were reported by 71 percent of patients assigned to linezolid and by 58 percent of the vancomycin group. Most adverse events were mild or moderate, but drug discontinuation was attributed to a drug adverse event in 8 percent of linezolid patients and 4 percent of vancomycin patients.

The authors conclude that clinical success rates were similar in patients treated with linezolid and vancomycin; however, significantly more patients treated with linezolid achieved microbiologic cure. The authors emphasize the growing significance of resistant infections in surgical practice and the need to develop effective oral agents.

ANNE D. WALLING, M.D.

Weigelt J, et al. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am J Surg December 2004;188:760-6.

COPYRIGHT 2005 American Academy of Family Physicians
COPYRIGHT 2005 Gale Group

Return to Zyvox
Home Contact Resources Exchange Links ebay